Pyxis Oncology develops antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies to enhance the immune response against difficult-to-treat cancers. Their targeted therapeutics aim to improve patient outcomes by delivering potent agents directly to tumor cells and activating the immune system to combat cancer's defense mechanisms.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are difficult to treat due to their resistance to existing therapies and their ability to evade the body's immune system. Traditional cancer treatments often lack specificity, leading to systemic toxicity and limited efficacy in targeting tumor cells.
Solution
Pyxis Oncology develops targeted cancer therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, designed to improve outcomes for patients with difficult-to-treat cancers. Their ADC platform delivers potent cancer-killing agents directly to tumor cells, enhancing efficacy while minimizing off-target effects. The company's immunotherapies aim to mobilize the body's immune system to attack cancer cells by blocking cancer's defense mechanisms and activating components of the immune system to overcome immune suppression. Pyxis Oncology is developing these assets as monotherapies and in combination with other therapies.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers and the healthcare professionals who treat them.
Features
- Antibody-drug conjugates (ADCs) designed to deliver potent cancer-killing agents directly to tumor cells.
- Monoclonal antibody (mAb) immunotherapies that mobilize the body’s immune system to attack cancer cells.
- Technology platform designed to develop safer and more effective ADCs.
- Immunotherapies that block cancer’s defense mechanisms.
- Immunotherapies that activate components of the immune system to overcome immune suppression.
- Clinical assets developed as monotherapies.
- Clinical assets developed in combination with other therapies.